DRKS00010992已完成不适用
Prospective Evaluation of Circulating Tumour DNA (ctDNA) as Molecular Monitoring Tool and Prognostic Biomarker in Resectable Pancreatic Adenocarcinomas - ctDNA in resektablen Pankreaskarzinomen
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- one 至 one（—）
- 性别
- All
入选标准
- •Key inclusion criteria are resectable pancreatic adenocarcinoma and curatively intended, macroscopically complete (R0/R1) resection.
排除标准
- •Key exclusion criteria are Stage IV metastatic disease diagnosed prior to or during surgery and Non-resectable tumour or macroscopically incomplete (R2) resection. Histology other than primary adenocarcinoma is also not included. Other key exclusion criteria are malignancies diagnosed within the previous five years of diagnosis (except non-melanoma skin cancer and carcinoma in situ of the cervix uteri).
研究者
相似试验
招募中
不适用
Circulating tumor DNA (ctDNA) analyses as a predictive marker for cancer treatment in solid tumorsKCT0008188Chonnam National University Hospital Hwasun Hospital100
进行中（未招募）
不适用
Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell LymphomasPeripheral T Cell LymphomaNCT06089941Centre Henri Becquerel45
招募中
不适用
Bespoke ctDNA Assay for Recurrence and Treatment Response Monitoring in Advanced Epithelial Ovarian CancerOvarian CancerNCT05446545Fudan University139
进行中（未招募）
4 期
CUARTET StudyMetastatic Castration-sensitive Prostate CancerJPRN-jRCTs071200040emura Hirotsugu100
Unknown
不适用
The Implication of ctDNA in the Recurrence Surveillance of Stage II and III Colorectal CancerctDNAColorectal CancerSurveillanceNCT03416478Sixth Affiliated Hospital, Sun Yat-sen University50